Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage pha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Philip, Philip A., Mahoney, Michelle R., Holen, Kyle D., Northfelt, Donald W., Pitot, Henry C., Picus, Joel, Flynn, Patrick J., Erlichman, Charles
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896238/
https://ncbi.nlm.nih.gov/pubmed/21953248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26556
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares